Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for treatment-resistant depression
ChiCTR2100043131Phase 4Completed
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Zhongda Hospital, Southeast University. Primary endpoints: HAMD reduction rate and Treatment-emergent symptom scale. Started Jan 2021; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2100043131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043131.